Immunomodulatory peptide (approved in multiple countries)
Tα1
An immune-modulating peptide with approved use in several countries for viral and immune conditions; research ongoing.
- Evidence:
- Moderate human evidence
- Status:
- Approved outside the U.S. (context-specific)
- Reviewed:
- 2026-08-03
Also known as: Tα1, Thymalfasin, Zadaxin
What is Tα1?
An immune-modulating peptide with approved use in several countries for viral and immune conditions; research ongoing.
This profile is educational. It organizes publicly discussed research context for Tα1 and related naming aliases — it is not a treatment guide.
Proposed mechanism
Enhances T-cell maturation and dendritic cell function; modulates TLR signaling and cytokine balance.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Moderate human evidence
Preclinical evidence grade: Strong human evidence
Thymosin alpha-1 (thymalfasin) is approved outside the US for hepatitis B/C and as immune adjuvant in some regions. Studied during COVID-19 for immune modulation. Human evidence is moderate within approved indications. Not FDA approved in the United States.
Key uncertainties
- FDA approval pathway
- Optimal use in emerging infections
Research areas being studied
- Immunomodulation
- Hepatitis
- Sepsis research
- Vaccine adjuvant
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Injection-site reactions
- Generally mild systemic effects in trials
Additional risks & considerations
- Immune system perturbation
- Indication-specific contraindications
Regulatory status
Approved outside the U.S. (context-specific)
Approved in multiple countries (e.g., Zadaxin); not FDA approved.
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is Tα1?
An immune-modulating peptide with approved use in several countries for viral and immune conditions; research ongoing.
How does Tα1 work (proposed mechanism)?
Enhances T-cell maturation and dendritic cell function; modulates TLR signaling and cytokine balance.
What is Tα1 being researched for?
Tα1 has been discussed in research contexts including: Immunomodulation, Hepatitis, Sepsis research, Vaccine adjuvant.
What does current evidence say about Tα1?
Moderate human evidence. Thymosin alpha-1 (thymalfasin) is approved outside the US for hepatitis B/C and as immune adjuvant in some regions. Studied during COVID-19 for immune modulation. Human evidence is moderate within approved indications. Not FDA approved in the United States.
What safety considerations are noted for Tα1?
Reported or discussed considerations include: Injection-site reactions; Generally mild systemic effects in trials; Immune system perturbation; Indication-specific contraindications. This is educational information, not medical advice.
Is Tα1 FDA approved?
Approved outside the U.S. (context-specific). Approved in multiple countries (e.g., Zadaxin); not FDA approved.
References & sources
- Dominari A et al. (2020). Thymosin alpha 1: from bench to bedside — Ann NY Acad Sci. Evidence type: review.
Prefer interactive tools? Open the PepGuide library entry for Tα1 or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.